Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

被引：35

作者：

Gutzmer, Ralf ^{[1
]}

Becker, Juergen C. ^{[2
]}

Enk, Alexander ^{[3
]}

Garbe, Claus ^{[4
]}

Hauschild, Axel ^{[5
]}

Leverkus, Martin ^{[6
]}

Reimer, Georg ^{[7
]}

Treudler, Regina ^{[8
]}

Tsianakas, Athanasios ^{[9
]}

Ulrich, Claas ^{[10
]}

Wollenberg, Andreas ^{[11
]}

Homey, Bernhard ^{[12
]}

机构：

[1] Hannover Med Sch, Skin Canc Ctr, Dept Dermatol Allergy & Venereol, D-30449 Hannover, Germany

[2] Graz Univ, Dept Dermatol & Venereol, A-8010 Graz, Austria

[3] Univ Heidelberg, Dept Dermatol, D-6900 Heidelberg, Germany

[4] Univ Tubingen, Dept Dermatol, Sect Dermatol Oncol, D-72074 Tubingen, Germany

[5] Univ Schleswig Holstein, Dept Dermatol Venereol & Allergy, Lubeck, Germany

[6] Univ Heidelberg, Univ Clin Mannheim, Dept Dermatol Venereol & Allergy, D-6900 Heidelberg, Germany

[7] Dermatol Off, Augsburg, Germany

[8] Univ Leipzig, Dept Dermatol Venereol & Allergy, Leipzig, Germany

[9] Univ Munster, Dept Dermatol, D-4400 Munster, Germany

[10] Charite, Dept Dermatol Venereol & Allergy, D-13353 Berlin, Germany

[11] Univ Munich, Dept Dermatol & Allergy, Munich, Germany

[12] Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2011年 / 9卷 / 03期

关键词：

EGFR; cutaneous side effects; papulopustular exanthema; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; QUALITY-OF-LIFE; SKIN TOXICITY; PHASE-III; CETUXIMAB; THERAPY; TRIAL; RASH; ERLOTINIB;

D O I：

10.1111/j.1610-0387.2010.07561.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely develop cutaneous side effects. The development of a papulopustular, follicular exanthema during the first weeks of therapy correlates with therapeutic benefit. However, this exanthema and other cutaneous side effects can impair the quality of life of the patient and might limit the therapy with the EGFR inhibitor. For an optimal therapeutic benefit and quality of life an adequate management of cutaneous side effects is necessary. A panel of German dermatologists developed on the basis of personal experience and current literature consensus recommendations for the management of cutaneous side effects of EGFR inhibitors.

引用

页码：195 / 202

页数：8

共 36 条

[1]

Alexandrescu Doru T, 2009, Dermatol Online J, V15, P4

[2]

[Anonymous], J CLIN ONCOL S

[3]

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck [J].

Bernier, J. ;

Bonner, J. ;

Vermorken, J. B. ;

Bensadoun, R-J. ;

Dummer, R. ;

Giralt, J. ;

Kornek, G. ;

Hartley, A. ;

Mesia, R. ;

Robert, C. ;

Segaert, S. ;

Ang, K. K. .

ANNALS OF ONCOLOGY, 2008, 19 (01) :142-149

[4]

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[5]

Trichomegaly of the eyelashes following treatment with cetuximab [J].

Bouché, O ;

Brixi-Benmansour, H ;

Bertin, A ;

Perceau, G ;

Lagarde, S .

ANNALS OF ONCOLOGY, 2005, 16 (10) :1711-1712

[6]

Brabender J, 2001, CLIN CANCER RES, V7, P1850

[7]

Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor [J].

Dainichi, T ;

Tanaka, M ;

Tsuruta, N ;

Furue, M ;

Noda, K .

DERMATOLOGY, 2003, 207 (03) :324-325

[8]

Epidermal growth factor receptor inhibition induces trichomegaly [J].

Dueland, S ;

Sauer, T ;

Lund-Johansen, F ;

Ostenstad, B ;

Tveit, KM .

ACTA ONCOLOGICA, 2003, 42 (04) :345-346

[9]

Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia [J].

Eames, T. ;

Grabein, B. ;

Kroth, J. ;

Wollenberg, A. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (08) :958-960

[10]

Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy [J].

Eames, Tatiana ;

Kroth, Julia ;

Flaig, Michael J. ;

Ruzicka, Thomas ;

Wollenberg, Andreas .

ACTA DERMATO-VENEREOLOGICA, 2010, 90 (02) :202-203

← 1 2 3 4 →